ZZZheng Zhang

Zheng Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zheng Zhang has a total of 130 co-authors. Here are the top co-authors by number of shared publications:

  • Wencong Han

    Department of Urology, Peking University First Hospital; Institution of Urology, Peking University; Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center; National Urological Cancer Center, Beijing, China

    12 shared publications
  • Xuesong Li

    Department of Urology, Peking University First Hospital & the Institute of Urology, Peking University, Beijing 100034, China

    7 shared publications
  • Liqun Zhou

    Department of Urology, Peking University First Hospital, Beijing, China; Institute of Urology, Peking University, Beijing, China; National Urological Cancer Center, Beijing, China

    5 shared publications
  • Qi Shen

    Department of Urology, Peking University First Hospital, Beijing, China

    5 shared publications
  • Shiwei Chen

    Department of Urology, Peking University First Hospital; Institution of Urology, Peking University; Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center; National Urological Cancer Center, Beijing, China

    5 shared publications
  • Tai Kang

    Department of Urology, Peking University First Hospital, Beijing, China

    5 shared publications

Latest Publications

  • Open Access

    Deep learning model for automatic detection of incidental adrenal abnormalities on low-dose computed tomography images

    by Kexin Wang, He Wang, Shiwei Chen, Wencong Han, Wenzhi Gao, Guangyong Shi, Tong Liu, Chongchen Ma, Jiangtao Liu, Xiangpeng Wang, et al.

    Background: To investigate the feasibility of employing deep learning models for automated segmentation and classification of adrenal incidental abnormalities on low-dose CT images. Methods: Four distinct CT cohorts were retrospectively collected for deep learning models development (cohort A, n = 2574; cohort B, n = 1205), internal evaluation (cohort C, n = 3681), and external evaluation (cohort D, n = 779). Two experienced uroradiologists independently reviewed the CT images and labeled the adrenal glands as normal or abnormal based on predefined criteria encompassing both density and morphological abnormalities, with any discrepancies resolved through consultation. The model development cohorts were divided into a training set, a validation set, and a test set. Deep learning models for segmentation and classification were trained and evaluated on internal and external sets, with the dice similarity coefficient (DSC), area under precision–recall curves (AUPRC), and area under receiver operating characteristic curves (AUROC) as evaluation metrics. Adrenal descriptions from radiology reports were extracted to compare with the model’s performance. Results: For adrenal gland segmentation, the DSC values for the test set, internal validation cohort, and external validation cohort were 0.839 (IQR: 0.783–0.871), 0.870 (IQR: 0.819–0.902), and 0.799 (IQR: 0.729–0.849), respectively. For adrenal gland classification, the AI model achieved AUPRC values of 0.913, 0.753, and 0.927 in the test set, internal validation cohort, and external validation cohort, respectively, outperforming routine radiology reporting (AUPRC: 0.809, 0.708, 0.591; all P < 0.05). Corresponding AUROC values were 0.956, 0.942, and 0.977 for the AI model, which also outperformed routine radiology reporting (AUROC: 0.889, 0.705, 0.551; all P < 0.05). Conclusions: The deep learning models showed promise in automated adrenal segmentation and classification, highlighting AI’s potential to improve detection of adrenal abnormalities in LDCT scans. Trial registration: This study has been registered on ClinicalTrials.gov on August 25, 2025, with the unique identifier NCT07198152.

  • Open Access

    Efficacy and safety of pralsetinib in multiple endocrine neoplasia type 2-associated pheochromocytoma: a case report

    by Shiwei Chen, He Wang, Qi Shen, Wencong Han, Kun Peng, Tai Kang, Zejin Ou, Zheng Zhang

    A 34-year-old male developed bilateral recurrent pheochromocytomas 10 years after laparoscopic adrenal-sparing surgery for pheochromocytomas. Based on his clinical manifestations and germline REarranged during Transfection (RET) variant, the patient was ultimately diagnosed with multiple endocrine neoplasia type 2B. Based on drug susceptibility testing results from organoid-guided precision therapy, the patient underwent secondary adrenalectomy for the right lesion and received oral pralsetinib to control the left ones. Over 16 months of pralsetinib therapy, we found that the patient achieved sustained therapeutic benefits, specifically characterized by symptomatic relief, significant reduction in hormone levels, and shrinkage of the left adrenal masses. These findings indicate that pralsetinib is effective and safe for treating pheochromocytomas associated with RET missense mutation, but further clinical practices are warranted to confirm its efficacy and safety profile.


  • Open Access

    Survival outcomes and prognostic predictors after adrenalectomy for renal cell carcinoma adrenal metastasis

    by Wencong Han, Kun Peng, Zejin Ou, Shiwei Chen, Tai Kang, Xiaoteng Yu, Zheng Zhang

    Purpose To evaluate survival outcomes after adrenalectomy for renal cell carcinoma (RCC) adrenal metastasis and to identify risk factors influencing overall survival. Methods We retrospectively reviewed all histologically confirmed cases of RCC adrenal metastasis managed at a tertiary center from January 2013 to December 2024. Overall survival (OS) was estimated with Kaplan–Meier analysis and compared with log-rank tests. Prognostic factors were examined using univariable and multivariable Cox proportional hazards models. Results A total of 82 patients with RCC adrenal metastasis were included (median age 60.5 years; IQR 54.8–67.0). Metachronous disease was present in 52 patients (63.4%), and 8 (9.8%) had bilateral adrenal involvement. Seventy-one patients (86.6%) underwent adrenalectomy; seven with bilateral primary renal tumors were excluded owing to indeterminate timing and/or laterality, leaving 64 for survival analysis. After a median follow-up of 32.5 months (IQR 14.8–80.8), the 1-, 3-, and 5-year OS rates were 96.6% (95% CI 92.2–100.0%), 87.1% (95% CI 77.8–97.6%), and 74.4% (95% CI 61.4–90.2%), respectively. Log-rank analysis showed poorer OS for synchronous presentation (P = 0.02), RCC T3/4 stage (P < 0.001), and primary tumor diameter > 6 cm (P = 0.001). In multivariable Cox analysis, increasing primary tumor diameter was the only independent predictor of reduced OS (HR 1.33, 95% CI 1.02–1.75; P = 0.04). Conclusions Adrenalectomy provides durable survival for well-selected patients with isolated or oligometastatic RCC adrenal metastasis. Prospective multicenter trials comparing surgery with non-surgical modalities are needed to refine management algorithms.


  • Open Access

    Clinical characteristics and survival outcomes of TFE3-rearranged renal cell carcinoma: a retrospective study compared with clear cell renal cell carcinoma using propensity score matching

    by Wencong Han, Kun Peng, Qi Shen, Shiwei Chen, Zejin Ou, Tai Kang, Xiaojun Yu, Jianbin Zhang, Zheng Zhang

    Section Background TFE3-rearranged renal cell carcinoma (TFE3-rRCC) is a rare subtype of RCC. This study aims to compare the clinical characteristics and survival outcomes with clear cell RCC (ccRCC) and explore the feasibility of partial nephrectomy (PN) in early-stage TFE3-rRCC patients. AbstractSection Materials and Patients This retrospective cohort study included 62 patients with TFE3-rRCC who underwent surgical resection at Peking University First Hospital between 2016 and 2024. Propensity score matching (PSM) was applied to match TFE3-rRCC patients with ccRCC patients. Clinical characteristics and survival outcomes were compared between the two groups. AbstractSection Results The median age of TFE3-rRCC patients at diagnosis was 33.0 years, with a female predominance (61.3%). The majority of patients were asymptomatic (61.3%). Before PSM, TFE3-rRCC patients were significantly younger and had a higher proportion of pT > 2 tumors compared to ccRCC patients (P < 0.01). After 1:2 PSM, survival outcomes in terms of progression-free survival (PFS) and overall survival (OS) were comparable between TFE3-rRCC and ccRCC in early-stage tumors. In patients with T > 2 tumors, a trend toward worse PFS was observed in the TFE3-rRCC group, though it did not reach statistical significance (P = 0.08). No significant differences in PFS and OS were observed between TFE3-rRCC and ccRCC for patients undergoing PN. AbstractSection Conclusion TFE3-rRCC should be stratified for a more accurate prognosis. Early-stage TFE3-rRCC demonstrates survival outcomes similar to those of ccRCC, and partial nephrectomy is a viable treatment approach for these patients.


  • Open Access

    Clinical features and management strategies of ectopic kidney: a 25-year single-center retrospective analysis

    by Wencong Han, Jingjing Gao, Shiwei Chen, Zejin Ou, Tai Kang, Xiaoteng Yu, Zheng Zhang, Xuesong Li

    Background: Ectopic kidney is a rare congenital anomaly characterized by abnormal renal ascent and frequent structural variants that predispose to urologic complications. This study aimed to investigate the clinical features, anatomical variations, and treatment strategies in patients with ectopic kidneys to inform individualized management. Methods: This single-center retrospective cohort included 95 patients (100 ectopic kidneys). Clinical data, including imaging findings, complications and treatment modalities, were collected. Anatomical characteristics, such as the location, rotation, and vascular variations of the ectopic kidneys, were evaluated through imaging. Surgical interventions were performed for urolithiasis, hydronephrosis and renal tumor patients. Results: The median diagnostic age was 37.0 years [interquartile range (IQR), 22.5–57.0 years], with 51/95 (53.7%) patients male and 44/95 (46.3%) female. Among the 100 ectopic kidneys, 63 (63.0%) were located in the pelvis, 24 (24.0 %) in the iliac fossa and 13 (13.0%) in the abdomen. Malrotation was observed in 55 of the 60 ectopic kidneys evaluated (91.7%). Vascular variations, including multiple vessels and anomalous origins, were common. Sixty patients (63.2%) were asymptomatic, whereas 14 (14.7%) reported abdominal or lumbar pain and 6 (6.3%) presented with hematuria. Urolithiasis affected 12 kidneys (12.0%), hydronephrosis occurred in 15 (15.0%), and renal tumors were present in 6 cases (6.0%). Twenty-six patients underwent surgery: 9 (34.6%) received transurethral endoscopic procedures, 8 (30.8%) underwent open surgery and 9 (34.6%) had laparoscopic surgery. Conclusions: Ectopic kidneys are frequently associated with structural abnormalities, such as malrotation and vascular variations, and are predisposed to complications, including urolithiasis and hydronephrosis. Early diagnosis, individualized treatment, and lifelong follow-up are essential for improving patient outcomes.


  • Open Access

    Robot-assisted urological tumor surgery using the MP1000 system: A prospective, single-center, single-arm clinical study

    by Mingxin Diao, Wenzhi Gao, Kunlin Yang, Yaming Gu, Zhihua Li, Xinfei Li, Zihui Gao, Xuesong Li, Zheng Zhang

    Objectives: This study is aimed to evaluate the safety and efficacy of the MP1000 robotic system in urological tumor surgery. Materials and methods: This prospective, single-center, single-arm clinical study evaluated data from urological tumor surgeries between June 2023 and December 2023. Patient demographics and perioperative outcomes were prospectively collected, and postoperative complications and success rates were analyzed. Ergonomics were assessed using the National Aeronautics and Space Administration Task Load Index. Results: A total of 28 patients underwent surgery during the study period. All procedures were successfully completed without conversion to standard laparoscopic or open surgery. All cases had negative surgical margins postoperatively, and no recurrences were observed within 3 months. The median glomerular filtration rate (GFR) at the third month after partial nephrectomy was 87.4 mL/min/1.73 m 2 (range, 55.64–124.33 mL/min/1.73 m 2 ). The median GFR at the third month after nephroureterectomy was 65.52 mL/min/1.73 m 2 (range, 65.52–98.12 mL/min/1.73 m 2 ). The GFR at the third month after radical nephrectomy was 57.22 mL/min/1.73 m 2 . The median prostate-specific antigen level for patients after radical prostatectomy was 0.01 ng/mL (range, 0–0.03 ng/mL) at 3 months. The short-term surgical success rate was 100%. Surgeons reported high comfort levels, with an overall National Aeronautics and Space Administration Task Load Index score of 12.89 ± 7.14. Conclusions: Based on our single-center experience, the MP1000 system demonstrated promising safety and efficacy in a variety of urological tumor surgeries.

  • Open Access

    Robot-assisted upper urinary tract repair surgery using the MP1000 system: a prospective, single-center, single-arm clinical study

    by Bing Wang, Wenzhi Gao, Kunlin Yang, Yaming Gu, Zhihua Li, Xinfei Li, Zihui Gao, Zheng Zhang, Xuesong Li

    Background: The MP1000 system is a newly developed surgical robot in China. This study, based on our single-center experience, evaluates its feasibility, safety, and effectiveness in upper urological repair surgeries. Methods: This prospective, single-center, single-arm clinical study was conducted from June 2023 to December 2023. One surgeon performed 20 upper urinary tract repair operations using the MP1000 system. Prospective demographic data and perioperative outcomes were collected, and postoperative complications and success rates were analyzed. The ergonomics were evaluated using national aeronautics and space administration task load index (NASA-TLX). Results: All cases were successfully completed without the need to switch to standard laparoscopic or open surgery. The average docking time was 4.1 [interquartile range (IQR), 3–5] min, the average control time was 145.1 (IQR, 102–195) min, and the average operation time was 189.1 (IQR, 145–248) min. The average estimated blood loss (EBL) was 58.5 (IQR, 20–100) mL. The mean length of stay was 6.95 (IQR, 4–8) days. All patients had no postoperative lumbago symptoms and no Clavien-Dindo grade III or higher-grade complications. The estimated glomerular filtration rate (eGFR) was 99.29 (IQR, 95.39–126.14) mL/min/1.73 m2 on the first day after surgery, 101.13 (IQR, 89.73–124.7) mL/min/1.73 m2 on the third day after surgery, and 78.38 (IQR, 57.12–91.84) mL/min/1.73 m2 on the third months after surgery. The short-term success rate was 100%. The overall score of NASA-TLX is 6.70±4.81. Conclusions: The MP1000 system is safe and effective for a variety of upper urinary tract repair procedures.


  • Open Access

    Modified percutaneous nephropexy for nephroptosis: Technical description and short-term results

    by Honglei Liu, Wenzhi Gao, Zheng Zhang, Kunlin Yang, Chang Meng, Bing Wang, Yangjun Han, Mingxin Diao, Chao Zuo, Minghua Zhang, et al.

    Objectives: Percutaneous nephropexy (PCN) has been demonstrated as a feasible method for treating nephroptosis. This study describes an improved technique for PCN that better addresses the issue of nephroptosis. Materials and methods: We reviewed 4 patients who underwent the improved PCN procedure between January 2021 and January 2023. These patients were diagnosed with nephroptosis, with 1 case having both a narrow ureteropelvic junction and nephroptosis due to a kidney stone, and 3 cases having simple nephroptosis. Patient characteristics, perioperative data, and follow-up results were collected. Surgical success was determined by symptom relief (subjective success) and the absence of kidney descent by intravenous pyelography (objective success). Results: Preoperative computed tomography urography showed that all patients had hydronephrosis, with severe hydronephrosis in 75% (3/4) and moderate hydronephrosis in 25% (1/4) of cases. The mean operative time was 63.8 minutes (range, 45–95 minutes), and the mean blood loss was 5 mL (range, 5–50 mL). The mean length of hospital stay was 4.5 days (range, 3–6 days). The mean time to removal of the nephrostomy tube was 2 months (range, 1–4 months). No serious complications (Clavien-Dindo grade ≥3) occurred during or after the procedure. The mean postoperative serum creatinine level was 54.75 μmol/L (range, 43–65 μmol/L). The mean follow-up time was 6.25 months (range, 4–8 months). The objective and subjective success rates were both 100%. Conclusions: The improved PCN procedure that was used in this study is feasible and provides a good option for treating nephroptosis.


  • Open Access

    68Ga-pentixafor PET/CT Is a Supplementary Method for Primary Aldosteronism Subtyping Compared with Adrenal Vein Sampling

    by Tieci Yi, Difei Lu, Yonggang Cui, Zheng Zhang, Xing Yang, Jianhua Zhang, Lin Qiu, Haoyu Weng, Lin Liu, Xiaojiang Duan, et al.

    Purpose: To investigate the diagnostic efficacy of 68Ga-pentixafor positron emission tomography/computed tomography (PET/CT) in primary aldosteronism (PA) subtyping and lateralization of aldosterone secretion in PA patients. Procedures: 37 patients who were diagnosed with PA, were prospectively enrolled in the study, and underwent adrenal vein sampling (AVS) after 68Ga-pentixafor PET/CT was conducted. Lateralization index (LI), defined as aldosterone/cortisol ratio in the dominant side to the contralateral adrenal vein when bilateral adrenal vein catheterization succeeded, and the aldosterone/cortisol ratio in the left adrenal vein to IVC (LAV/IVC) when the catheterization of right adrenal vein failed, were applied to determine lateralization side. Statistical analysis was performed using SPSS 21.0. Results: The female proportion of all patients with PA was 32.4% (12/37), and the mean age was 51.3 ± 10.9 years. Patients with bilateral adrenal mass accounted for 54.1% (20/37), and 10 of them (27.0%) had adrenal hyperplasia or adrenal nodules ≤ 1.0 cm. In all 37 patients, the sensitivity, specificity and accuracy of 68Ga-pentixafor PET/CT in distinguishing lateralization by visualization were 89.3%, 77.8% and 86.5%, respectively. The area under the ROC curve for detecting positive lateralization based on the value of 68Ga-pentixafor SUVmax was 0.750 (95%CI 0.578–0.922, p = 0.026). The optimum SUVmax cut-off value was 6.86, with the sensitivity of 78.6%, specificity of 66.7%, and accuracy of 78.4%. Defining SUV ratio as SUVmax/SUV of contralateral adrenal gland, the area under the ROC curve for identifying lateralization based on the SUV ratio was 0.710 (95%CI 0.500–0.921, p = 0.061). The optimum SUV ratio cut-off was 2.40, with the sensitivity of 60.7%, specificity of 88.9%, and accuracy of 67.6%. The consistency of 68Ga-pentixafor PET/CT with AVS was of no significant difference between patients with bilateral adrenal lesions (80.0%, 16/20) and unilateral lesion (94.1%, 16/17; p = 0.737), and no significance was revealed in the consistency between patients with adrenal hyperplasia or adrenal lesion of diameter ≤ 1 cm (81.8%, 9/11) and those with adrenal lesions > 1 cm (88.5%, 23/26; p = 0.884). Conclusions: 68Ga-pentixafor PET/CT showed at least 80% consistency for the lateralization in patients with PA compared with AVS, even in those presented with bilateral adrenal hyperplasia. Visual analysis exhibited better diagnostic efficacy compared with SUVmax or SUVmax/SUV of the contralateral adrenal gland.( ChiCTR2300073049. Registered 30 June 2023. Retrospectively registered)